AKUMS - Fundamental Analysis: Financial Health & Valuation
Back to ListFundamental Rating: 2.7
| Stock Code | AKUMS | Market Cap | 8,200 Cr. | Current Price | 521 ₹ | High / Low | 623 ₹ |
| Stock P/E | 70.4 | Book Value | 154 ₹ | Dividend Yield | 0.00 % | ROCE | 6.82 % |
| ROE | 4.93 % | Face Value | 2.00 ₹ | DMA 50 | 514 ₹ | DMA 200 | 497 ₹ |
| Chg in FII Hold | 0.24 % | Chg in DII Hold | -0.05 % | PAT Qtr | 17.1 Cr. | PAT Prev Qtr | 31.0 Cr. |
| RSI | 47.9 | MACD | 0.90 | Volume | 2,29,958 | Avg Vol 1Wk | 3,91,062 |
| Low price | 409 ₹ | High price | 623 ₹ | PEG Ratio | -3.46 | Debt to equity | 0.02 |
| 52w Index | 52.3 % | Qtr Profit Var | -38.1 % | EPS | 7.09 ₹ | Industry PE | 30.5 |
📊 Financial Overview:
AKUMS shows weak financial performance with quarterly PAT dropping from ₹31 Cr. to ₹17.1 Cr., reflecting declining profitability. ROCE at 6.82% and ROE at 4.93% are low, indicating poor capital efficiency. Debt-to-equity is minimal at 0.02, which is positive, but EPS at ₹7.09 remains modest. Cash flows appear pressured due to falling profits.
💹 Valuation Indicators:
The stock trades at a high P/E of 70.4, well above the industry average of 30.5, suggesting overvaluation. P/B ratio is ~3.4 (521 ÷ 154), which is moderate. PEG ratio is negative (-3.46), reflecting declining earnings growth. Dividend yield is 0%, reducing attractiveness for income investors. Intrinsic value appears lower than current price, limiting upside potential.
🏢 Business Model & Advantage:
AKUMS operates in pharmaceuticals and contract manufacturing, benefiting from India’s healthcare demand. Its competitive advantage lies in manufacturing scale and industry presence. However, weak return metrics and declining profits limit overall health. Institutional sentiment is mixed, with FIIs increasing slightly (+0.24%) while DIIs reduced (-0.05%).
📈 Entry Zone:
Technically, support lies near ₹497 (200 DMA) and ₹514 (50 DMA). A cautious entry zone would be between ₹490–₹510 if valuations cool down. Long-term holding requires improvement in profitability and return ratios before confidence can be restored.
Positive
- 📌 Debt-to-equity is very low (0.02), ensuring financial stability.
- 📌 FII holdings increased slightly (+0.24%), showing some foreign confidence.
- 📌 Reasonable P/B ratio (~3.4) compared to peers.
Limitation
- ⚠️ High P/E (70.4) compared to industry average (30.5).
- ⚠️ Weak ROCE (6.82%) and ROE (4.93%).
- ⚠️ Quarterly PAT dropped sharply (-38.1%).
- ⚠️ No dividend yield, reducing investor appeal.
Company Negative News
- 📰 Reported significant decline in quarterly profits, raising concerns about sustainability.
Company Positive News
- 📰 Debt-free structure provides financial resilience.
- 📰 Slight increase in FII holdings reflects cautious optimism.
Industry
- 🌐 Pharmaceutical industry continues to expand with rising healthcare demand.
- 🌐 Industry P/E at 30.5 reflects growth potential, but AKUMS trades at a steep premium.
Conclusion
✅ AKUMS benefits from a debt-free balance sheet and presence in a growing industry. However, weak return ratios, declining profits, and stretched valuations make it risky for fresh entry. Entry is only advisable near support levels (₹490–₹510) with caution. Long-term holding requires improvement in profitability and efficiency to justify sustained investment.
For a broader perspective, you could explore a peer comparison or a pharma sector outlook to see how AKUMS stacks up against competitors.